Trial Profile

A Clinical Study to Investigate the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evogliptin (Primary)
Indications Aortic valve stenosis; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors Dong-A ST

Most Recent Events

24 Mar 2023 Results (n=16) assessing the possible effect of hemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
29 Nov 2021 Status changed from recruiting to completed.
13 Apr 2021 Planned End Date changed from 28 Feb 2020 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com